Frequency, risk factors, and impacts on quality of life of the restless legs syndrome and side effects among antidepressant users in a tertiary hospital: an observational cross-sectional study.

IF 2.5 3区 医学 Q3 PHARMACOLOGY & PHARMACY International Clinical Psychopharmacology Pub Date : 2023-07-01 DOI:10.1097/YIC.0000000000000466
Hatice Cetin Erdem, Huseyin Kara, Ozgen Ozcelik, Levent Donmez, Mehmet Eryilmaz, Gul Ozbey
{"title":"Frequency, risk factors, and impacts on quality of life of the restless legs syndrome and side effects among antidepressant users in a tertiary hospital: an observational cross-sectional study.","authors":"Hatice Cetin Erdem,&nbsp;Huseyin Kara,&nbsp;Ozgen Ozcelik,&nbsp;Levent Donmez,&nbsp;Mehmet Eryilmaz,&nbsp;Gul Ozbey","doi":"10.1097/YIC.0000000000000466","DOIUrl":null,"url":null,"abstract":"<p><p>Restless leg syndrome (RLS) is a common but underestimated sensorimotor disorder that significantly affects the quality of life (QoL) which can be induced by antidepressants. This study aims to investigate the frequency and potential risk factors of RLS and side effects in selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors (SSRI/SNRI) users. This cross-sectional study included 198 outpatients who received SSRI/SNRI for 4-8 weeks. Clinical evaluation was performed using the International Restless Leg Syndrome Study Group rating scale for RLS, Udvalg for Kliniske Undersøgelser side effects rating scale, and a short form 36 (SF-36) questionnaire for QoL. The frequency of RLS was 25%. RLS significantly increased with smoking and habituality. Also, habituality increased neurologic side effects reporting. The use of antipsychotics and calcium channel blockers decreased reporting of autonomic side effects. QoL decreased with RLS, psychiatric, neurologic, autonomic, and other side effects in different domains of SF-36. These findings suggested that SSRI/SNRI use could be associated with a higher risk of RLS, especially in smokers. QoL could be influenced negatively by RLS and all side effects. However, further prospective studies are needed to confirm these associations in large samples.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"38 4","pages":"209-215"},"PeriodicalIF":2.5000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YIC.0000000000000466","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Restless leg syndrome (RLS) is a common but underestimated sensorimotor disorder that significantly affects the quality of life (QoL) which can be induced by antidepressants. This study aims to investigate the frequency and potential risk factors of RLS and side effects in selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors (SSRI/SNRI) users. This cross-sectional study included 198 outpatients who received SSRI/SNRI for 4-8 weeks. Clinical evaluation was performed using the International Restless Leg Syndrome Study Group rating scale for RLS, Udvalg for Kliniske Undersøgelser side effects rating scale, and a short form 36 (SF-36) questionnaire for QoL. The frequency of RLS was 25%. RLS significantly increased with smoking and habituality. Also, habituality increased neurologic side effects reporting. The use of antipsychotics and calcium channel blockers decreased reporting of autonomic side effects. QoL decreased with RLS, psychiatric, neurologic, autonomic, and other side effects in different domains of SF-36. These findings suggested that SSRI/SNRI use could be associated with a higher risk of RLS, especially in smokers. QoL could be influenced negatively by RLS and all side effects. However, further prospective studies are needed to confirm these associations in large samples.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
三级医院抗抑郁药使用者中不宁腿综合征的频率、危险因素、对生活质量的影响和副作用:一项观察性横断面研究
不宁腿综合征(RLS)是一种常见但被低估的感觉运动障碍,它显著影响生活质量(QoL),可由抗抑郁药诱导。本研究旨在探讨选择性5 -羟色胺再摄取抑制剂/ 5 -羟色胺和去甲肾上腺素再摄取抑制剂(SSRI/SNRI)服用者发生RLS的频率、潜在危险因素及副作用。本横断面研究纳入198例接受SSRI/SNRI治疗4-8周的门诊患者。采用国际不宁腿综合征研究组RLS评定量表、Udvalg Kliniske Undersøgelser副作用评定量表和SF-36生活质量问卷进行临床评价。RLS发生率为25%。RLS随吸烟和习惯的增加而显著增加。此外,习惯增加了神经副作用的报告。抗精神病药物和钙通道阻滞剂的使用减少了自主神经副作用的报告。生活质量随SF-36不同领域的RLS、精神、神经、自主神经和其他副作用而下降。这些发现表明,SSRI/SNRI的使用可能与RLS的高风险相关,尤其是吸烟者。RLS及所有副作用均对生活质量有负面影响。然而,需要进一步的前瞻性研究在大样本中证实这些关联。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.40
自引率
23.10%
发文量
97
审稿时长
>12 weeks
期刊介绍: International Clinical Psychopharmacology provides an essential link between research and clinical practice throughout psychopharmacology. It reports on studies in human subjects, both healthy volunteers and patients, which relate the effects of drugs on psychological processes. A major objective of the journal is to publish fully refereed papers which throw light on the ways in which the study of psychotropic drugs can increase our understanding of psychopharmacology. To this end the journal publishes results of early Phase I and II studies, as well as those of controlled clinical trials of psychotropic drugs in Phase II and IV. Other topics covered include the epidemiology of psychotropic drug prescribing and drug taking, the sociology of psychotropic drugs including compliance, and research into the safety and adverse effects of these compounds.
期刊最新文献
Immediate-release vs. prolonged-release lithium formulations in bipolar disorder: a 2-year comparative study. Prevalence and correlates of prescription drug abuse and misuse among adult prisoners: a systematic review. Effects of transcranial direct current stimulation (tDCS) at different cortical targets on cognition in obsessive-compulsive disorder (OCD): an exploratory analysis. Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial. Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1